Overview

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

Status:
Completed

Trial end date:
2014-02-27

Target enrollment:

Participant gender:

Summary

The goal of this study is to determine if Hylenex recombinant leads to changes in the insulin time-action profiles and glucose responses when preadministered in the setting of continuous subcutaneous insulin infusion (CSII) compared to CSII without Hylenex recombinant (sham injection).

Phase:

Phase 4

Details

Lead Sponsor:

Halozyme Therapeutics

Treatments:

Insulin
Insulin, Globin Zinc
Insulin, Short-Acting